| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000023917 |
| Receipt No. | R000027543 |
| Official scientific title of the study | Evaluation of the effects of OATP1B1*15 on the plasma concentrations of endogenous compounds (metabolome analysis) |
| Date of disclosure of the study information | 2016/09/03 |
| Last modified on | 2018/03/05 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Evaluation of the effects of OATP1B1*15 on the plasma concentrations of endogenous compounds (metabolome analysis) | |
| Title of the study (Brief title) | Exploration for the biomarkers for OATP1B1*15 | |
| Region |
|
|
| Condition | ||
| Condition | healthy male and female | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | 1) to explore the biomarkers for OATP1B1*15
2) to investigate the circadian rhythm of endogenous compounds 3) to evaluate the effects of OATP1B1*15 on the pharmacokinetics of substrates |
| Basic objectives2 | Pharmacokinetics |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | the plasma concentrations of endogenous compounds
pharmacokinetics of atorvastatin, pitavastatin, rosuvastatin, and fluvastatin |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | substrate cocktail | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | The investigators must ensure that all subjects being considered meet the following
inclusion criteria: 1) Japanese healthy male or female who is capable to understand and sign the informed consent 2) 20-45 years of age 3) BMI 17.6-26.4 4) good health as determined by physical examination, vital signs and laboratory tests. |
|||
| Key exclusion criteria | The investigators must ensure that all subjects being considered meet the following
exclusion criteria or conditions: 1) history of allergy to any drugs 2) medical attention within 2 months prior to participation 3) donation of 200 mL or more of blood within 4 weeks prior to participation, or donation of component blood within 2 weeks prior to participation 4) donation of 400 mL or more of blood within 12 weeks prior to participation 5) recent (past 4 months) participation in other clinical trial for investigational new chemical entity 6) history of drug abuse 7) alcohol abuse. 8) lactose intolerance 9) taking drugs or healthy foods which may affect drug metabolism |
|||
| Target sample size | 26 | |||
| Research contact person | |
| Name of lead principal investigator | Shunji Matsuki |
| Organization | LTA |
| Division name | Fukuoka Mirai Hospital |
| Address | 3-5-1, Kashiiteruha, Higashi-ku, Fukuoka |
| TEL | 092-662-3608 |
| shunji-matsuki@lta-med.com | |
| Public contact | |
| Name of contact person | Miyuki Kimura |
| Organization | LTA |
| Division name | Fukuoka Mirai Hospital |
| Address | 3-5-1, Kashiiteruha, Higashi-ku, Fukuoka |
| TEL | 092-662-3608 |
| Homepage URL | |
| miyuki-kimura@lta-med.com | |
| Sponsor | |
| Institute | Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japanese Society for the Promotion of Science |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027543 |